Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2013

Mazzoni Francesca, Cecere Fabiana Letizia, Meoni Giulia, Giuliani Costanza, Boni Luca, Camerini Andrea, Lucchesi Sara, Martella Francesca, Amoroso Domenico, Lucherini Elisa, Torricelli Francesca, Di Costanzo Francesco

Abstract excerpt

OBJECTIVES: Customized chemotherapy has several advantages: patients are more likely to be treated with the most effective agents and can be spared the toxicity of ineffective drugs. Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Endonucleases

Share to Gemcitabine

Share to Neoplasm Staging

Share to Ribonucleoside Diphosphate Reductase

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 24045016
DOI: 10.1016/j.lungcan.2013.08.018

Genes

ERCC1
RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24045016-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.PMID 24045016Read ↗

Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Semantic proximity Read ↗

Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.Semantic proximity Read ↗

Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.Semantic proximity Read ↗

Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read ↗

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.Semantic proximity Read ↗

Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.Semantic proximity Read ↗

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapySemantic proximity Read ↗

Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.